First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy has also shown no evidence of causing graft-versus-host disease, a condition where foreign immune cells attack the host body. Celyad’s CAR T-cell immunotherapy is aimed to overcome the drawbacks of CAR T-cell immunotherapies already in the market such as Kymriah and Yescarta.